Table 1. Test performance assumptions in MISCAN.
| Performance characteristic | Colonoscopy 1 | Sigmoidoscopy 2 | FOBT 3 |
|---|---|---|---|
| Sensitivity: | |||
| - Adenomas ≤ 5 mm | 0.75 | 0.75 | - |
| - Adenomas 6 - 9 mm | 0.85 | 0.85 | 0.013 |
| - Adenomas ≥ 10 mm | 0.95 | 0.95 | 0.065 |
| - Stage I adenocarcinoma | 0.95 | 0.95 | 0.182 / 0.508 |
| - Stage II adenocarcinoma | 0.95 | 0.95 | 0.182 / 0.508 |
| - Stage III adenocarcinoma | 0.95 | 0.95 | 0.182 / 0.508 |
| - Stage IV adenocarcinoma | 0.95 | 0.95 | 0.182 / 0.508 |
| Specificity: | NA | NA | 0.02 |
| Reach endoscope: | Cecum | Splenic Flexure | NA |
| Completeness rate:4 | 0.98 | 0.80 | NA |
FOBT = Fecal Occult Blood Testing; iFOBT = immunochemical FOBT; NA = Not Applicable
1
Colonoscopy sensitivity for each adenoma, and completeness of colonoscopy were based on a systematic review of adenoma miss rates in tandem colonoscopy studies by Van Rijn and colleagues(42).
2
Sensitivity of sigmoidoscopy was also based on van Rijn and colleagues (42).
3
We assumed that fecal occult blood testing is more sensitive in preclinical cancers that are close time-wise to becoming symptomatic. This assumption showed good concordance with Fecal Occult Blood Test trial results (48).
4
This is the proportion of endoscopies visualizing the maximum point of reach of the endoscope.